Error loading player: No playable sources found
64044
CASSS Welcome & CGTP Summit 2023 Introduction
Date
June 26, 2023
This product is not available for individual purchase, but it is available as part of the following products:
The Cell and Gene Therapy Products (CGTP) Symposium: Manufacturing, Quality and Regulatory Considerations enables the exchange of scientific ideas and dialogue with regulators that form the basis of evolving regulatory practices in the development of these diverse and innovative products…
Comparability assessments are necessary for life cycle management of all biological products, including cell and gene therapies (CGT), and are conducted to ensure that manufacturing changes do not adversely impact product quality, safety, or efficacy. The complexity and diversity of CGT product modalities can pose considerable challenges to the usual approaches, which are guided by the principles in ICH Q5E. In this summit, we will discuss a range of CGT modalities and some new concepts in comparability required for certain CGT products.
Session Chair
General
Tracks
Related Products
Session 2: Comparability Considerations for Cell-Based Therapies
Comparability assessments for cell-based therapies are challenging due to complex manufacturing processes, inherent variability of cell starting materials, and evolving understanding of product quality attributes and analytical technologies…
Technical Seminar presented by MilliporeSigma
Ensuring the Virus Safety Profile of Your Product - Expectations and Recommendations From the Latest Update to ICH Q5A
Plenary Session 12: Updates in the Regulatory Landscape for Cell & Gene Therapy Products
Several cell and gene therapy products have received marketing approval from health authorities and, with that, a more complete picture is now emerging about the regulatory CMC requirements to commercialize these products…
